Mereo BioPharma Group PLC ADR

Mereo BioPharma Group plc is a biopharmaceutical company that develops and commercializes therapeutics for rare diseases in the United Kingdom and the United States. Its pipeline includes Setrusumab for osteogenesis imperfecta, Alvelestat for Alpha-1 anti-trypsin deficiency associated lung disease, Vantictumab for autosomal dominant osteopetrosis type 2, Leflutrozole for hypogonadotropic hypogonadism, Navicixizumab for late-line ovarian cancer, Etigilimab for advanced solid tumors, and Acumapimod for acute exacerbations of chronic obstructive pulmonary disease. The company has license agreements with Feng Biosciences for navicixizumab, ReproNovo for leflutrozole, and AstraZeneca. Incorporated in 2015, Mereo BioPharma Group plc is headquartered in London, United Kingdom.